PCSA advances VT-7208 into phase II trials
PCSA said a recent merger and a $200 million PIPE position it to advance VT-7208, a next-generation BTK inhibitor, into three parallel phase II trials targeting food allergy, CSU and relapsing MS.
A recent merger and a $200 million PIPE have positioned the company to advance VT-7208, a next-generation BTK inhibitor, into three parallel phase II trials targeting food allergy, CSU, and relapsing MS. VT-7208 7208 is described as showing strong safety, durable efficacy and differentiation from competitors.